PL3946322T3 - Sposoby przywracania wrażliwości na ttfields w komórkach nowotworowych opornych wobec ttfields, z inhibitorami ptger3 - Google Patents

Sposoby przywracania wrażliwości na ttfields w komórkach nowotworowych opornych wobec ttfields, z inhibitorami ptger3

Info

Publication number
PL3946322T3
PL3946322T3 PL20717971.4T PL20717971T PL3946322T3 PL 3946322 T3 PL3946322 T3 PL 3946322T3 PL 20717971 T PL20717971 T PL 20717971T PL 3946322 T3 PL3946322 T3 PL 3946322T3
Authority
PL
Poland
Prior art keywords
ttfields
ptger3
inhibitors
methods
cancer cells
Prior art date
Application number
PL20717971.4T
Other languages
English (en)
Inventor
David Tran
Son Bang LE
Dongjiang CHEN
Original Assignee
Novocure Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novocure Gmbh filed Critical Novocure Gmbh
Publication of PL3946322T3 publication Critical patent/PL3946322T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/205—Applying electric currents by contact electrodes continuous direct currents for promoting a biological process
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrotherapy Devices (AREA)
PL20717971.4T 2019-03-29 2020-03-27 Sposoby przywracania wrażliwości na ttfields w komórkach nowotworowych opornych wobec ttfields, z inhibitorami ptger3 PL3946322T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826078P 2019-03-29 2019-03-29
US201962849535P 2019-05-17 2019-05-17
PCT/IB2020/052959 WO2020201967A1 (en) 2019-03-29 2020-03-27 Methods for restoring sensitivity to ttfields in ttfields-resistant cancer cells with ptger3 inhibitors

Publications (1)

Publication Number Publication Date
PL3946322T3 true PL3946322T3 (pl) 2024-02-26

Family

ID=70228406

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20717971.4T PL3946322T3 (pl) 2019-03-29 2020-03-27 Sposoby przywracania wrażliwości na ttfields w komórkach nowotworowych opornych wobec ttfields, z inhibitorami ptger3

Country Status (7)

Country Link
US (2) US11911610B2 (pl)
EP (3) EP3977991A1 (pl)
JP (2) JP7419391B2 (pl)
CN (1) CN113613651B (pl)
DK (1) DK3946322T3 (pl)
PL (1) PL3946322T3 (pl)
WO (1) WO2020201967A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10779875B2 (en) 2013-05-06 2020-09-22 Novocure Gmbh Optimizing treatment using TTfields by changing the frequency during the course of long term tumor treatment
US10188851B2 (en) 2015-10-28 2019-01-29 Novocure Limited TTField treatment with optimization of electrode positions on the head based on MRI-based conductivity measurements
US10821283B2 (en) 2016-04-04 2020-11-03 Novocure Gmbh Reducing motility of cancer cells using tumor treating fields (TTFields)
EP3571503B1 (en) 2017-01-19 2026-04-15 Novocure GmbH System for viewing cell cultures under a microscope whilst applying ttfields
US11986647B2 (en) 2018-09-07 2024-05-21 Novocure Gmbh Treating autoinflammatory and mitochondrial diseases using an alternating electric field
HUE061361T2 (hu) 2018-10-15 2023-06-28 Novocure Gmbh Az egész agyban nagy egyenletességû tumorkezelõ mezõk (TT-mezõk) generálása
CN112955208B (zh) 2018-10-25 2024-11-22 诺沃库勒有限责任公司 向受试者的脊柱解剖结构递送交变电场(例如,ttfields)的方法
HUE065574T2 (hu) 2018-11-19 2024-06-28 Novocure Gmbh Tömbök daganatkezelõ mezõk (TTFIELD) rendelkezésre bocsátására szelektíven címezhetõ alelemekkel
JP7353363B2 (ja) 2018-11-29 2023-09-29 ノボキュア ゲーエムベーハー TTFields(腫瘍治療電場)を提供するための柔軟性を高めたトランスデューサーアレイ
EP3968279B1 (en) 2019-01-08 2025-01-01 Novocure GmbH Evaluating quality of segmentation of an image into different types of tissue for planning treatment using tumor treating fields (ttfields)
CN121314073A (zh) 2019-07-31 2026-01-13 诺沃库勒有限责任公司 经由埋入颅骨植入物中的电极施加肿瘤治疗场(TTField)
CN114390914A (zh) 2019-08-05 2022-04-22 诺沃库勒有限责任公司 通过抑制il11活性增加癌细胞对肿瘤治疗场(ttfield)的敏感性
US11890467B2 (en) 2019-08-30 2024-02-06 Novocure Gmbh Delivering tumor treating fields (TTFields) to the neck
HUE061733T2 (hu) 2019-12-31 2023-08-28 Novocure Gmbh Tömbök tumorkezelõ mezõk (TTFields) szállítására egyenként hozzáférhetõ elektródaelemekkel és hõmérsékletérzékelõkkel
US12121739B2 (en) 2019-12-31 2024-10-22 Novocure Gmbh Methods, systems, and apparatuses for managing temperatures induced by alternating fields
KR20220122679A (ko) 2019-12-31 2022-09-02 노보큐어 게엠베하 채널들의 스위칭 및 진폭 조정 중 스파이크들을 방지하는 고전압, 고효율 사인파 생성기
US20210299440A1 (en) 2020-03-30 2021-09-30 Novocure Gmbh Intravenous / Intra-Spinal / Intra-Cavity / Intraventricular Delivery of TTFields (Tumor Treating Fields) for Treating Cancer and Metastases
CN115916325A (zh) 2020-04-24 2023-04-04 诺沃库勒有限责任公司 使用交变电场增加血脑屏障的通透性
US11818943B2 (en) 2020-06-25 2023-11-14 Novocure Gmbh Fabricating organic light emitting diodes (OLEDs) using tubulin
EP4223363B1 (en) 2020-09-25 2024-04-24 Novocure GmbH Varying the metallization area on individual electrode elements in a tumor treating fields system to maximize current without overheating
US20220267445A1 (en) * 2021-02-17 2022-08-25 Novocure Gmbh Methods and Compositions for Determining Susceptibility to Treatment with Checkpoint Inhibitors
US20250101406A1 (en) 2022-09-23 2025-03-27 Novocure Gmbh 3d models for predicting treatment responses to alternating electric fields
US12558538B2 (en) 2023-09-29 2026-02-24 Novocure Gmbh Using staggered changes in amplitude and frequency to ameliorate electrosensation during treatment with alternating electric fields
WO2026003783A1 (en) * 2024-06-27 2026-01-02 Novocure Gmbh Compositions, systems, and methods for treating cancer using tumor treating fields (ttfields) and nf-κb inhibitors

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8447395B2 (en) 2000-02-17 2013-05-21 Novocure Ltd Treating bacteria with electric fields
US7136699B2 (en) 2002-10-02 2006-11-14 Standen, Ltd. Apparatus for destroying dividing cells
US7890183B2 (en) 2000-02-17 2011-02-15 Novocure Ltd. Treating parasites with electric fields
US8175698B2 (en) 2000-02-17 2012-05-08 Novocure Ltd. Treating bacteria with electric fields
US7089054B2 (en) 2002-10-02 2006-08-08 Standen Ltd. Apparatus and method for treating a tumor or the like
US6868289B2 (en) 2002-10-02 2005-03-15 Standen Ltd. Apparatus for treating a tumor or the like and articles incorporating the apparatus for treatment of the tumor
US7016725B2 (en) 2001-11-06 2006-03-21 Standen Ltd. Method and apparatus for destroying dividing cells
EP2335776A1 (en) 2000-02-17 2011-06-22 Yoram Palti Method and apparatus for destroying dividing cells
US7599746B2 (en) 2000-02-17 2009-10-06 Standen Ltd Apparatus and method for preventing the spread of cancerous metastases and for elimination of metastases
WO2005115535A2 (en) 2004-04-23 2005-12-08 Novocure Ltd. Treating a tumor or the like with electric fields at different frequencies
DK1833552T3 (da) 2004-12-07 2010-08-02 Standen Ltd Elektroder til anbringelse af et elektrisk felt in-vivo i en længere tidsperiode
CN102488967B (zh) 2004-12-27 2016-03-30 诺沃库勒有限公司 利用电场从不同方向治疗肿瘤等
DK3804809T3 (da) 2005-10-03 2024-02-12 Novocure Gmbh Optimering af egenskaberne af et elektrisk felt for at øge feltets effekt på proliferende celler
US8019414B2 (en) 2006-04-05 2011-09-13 Novocure Ltd. Treating cancer using electromagnetic fields in combination with other treatment regimens
US20100074896A1 (en) 2006-11-30 2010-03-25 The Johns Hopkins University Antagonists of pge2 ep3 receptors
DK2167194T3 (en) 2007-03-06 2017-06-19 Novocure Ltd TREATMENT OF CANCER USING ELECTROMAGNETIC FIELDS IN COMBINATION WITH PHOTODYNAMIC THERAPY
US8715203B2 (en) 2007-09-17 2014-05-06 Novocure Limited Composite electrode
UY32546A (es) * 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer
US9381176B2 (en) 2012-02-24 2016-07-05 Wisconsin Alumni Research Foundation E-prostanoid receptor, Ptger3, as a novel anti-diabetic therapeutic target
US9655669B2 (en) 2013-05-06 2017-05-23 Novocure Limited Optimizing treatment using TTFields by changing the frequency during the course of long term tumor treatment
US10779875B2 (en) 2013-05-06 2020-09-22 Novocure Gmbh Optimizing treatment using TTfields by changing the frequency during the course of long term tumor treatment
US20190117963A1 (en) 2014-07-25 2019-04-25 Loyalty Based Innovations, LLC Apparatus and method for treating multiple tumors in patients with metastatic disease by electric fields
US9910453B2 (en) 2015-09-25 2018-03-06 Novocure Limited High voltage, high efficiency sine wave generator with pre-set frequency and adjustable amplitude
US10188851B2 (en) 2015-10-28 2019-01-29 Novocure Limited TTField treatment with optimization of electrode positions on the head based on MRI-based conductivity measurements
US10821283B2 (en) 2016-04-04 2020-11-03 Novocure Gmbh Reducing motility of cancer cells using tumor treating fields (TTFields)
EP3478360B1 (en) 2016-06-30 2024-04-10 Novocure GmbH Arrays for longitudinal delivery of ttfields to a body
CA2972699A1 (en) 2016-07-10 2018-01-10 Novocure Limited Synchronizing tumor cells to the g2/m phase using ttfields combined with taxane or other anti-microtubule agents
CN116747438A (zh) 2016-08-18 2023-09-15 诺沃库勒有限责任公司 用于递送肿瘤治疗电场的阵列中的温度测量
EP3554631B1 (en) 2016-12-13 2022-03-23 Novocure GmbH Treating patients with ttfields with the electrode positions optimized using deformable templates
EP3571503B1 (en) 2017-01-19 2026-04-15 Novocure GmbH System for viewing cell cultures under a microscope whilst applying ttfields
US10369077B2 (en) * 2017-05-31 2019-08-06 Adienne Pharma & Biotech Sa Multi chamber flexible bag and methods of using the same
GB2567613A (en) * 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
TWI676483B (zh) * 2017-08-06 2019-11-11 強普生技股份有限公司 醫藥套組及其用途
CN112566665A (zh) 2018-04-09 2021-03-26 莫舍·吉拉迪 用TTFields和Aurora激酶抑制剂治疗肿瘤
US11650277B2 (en) 2018-04-10 2023-05-16 Novocure Gmbh TTField treatment with optimization of electrode positions based on low frequency (<1MHZ) AC conductivity estimates derived from two MRI images having different repetition times
KR102870236B1 (ko) 2018-07-03 2025-10-14 에드윈 창 세포막 투과성을 향상시키기 위한 교류 전기장 사용
US11179322B2 (en) 2018-07-10 2021-11-23 Novocure Gmbh Methods and compositions for treating tumors with TTFields and sorafenib
IL279253B2 (en) 2018-07-18 2025-09-01 Novocure Gmbh Using power loss density and related measurements to quantify dose of tumor treatment fields
MX2020013519A (es) 2018-08-23 2021-05-12 Novocure Gmbh Uso de campos electricos alternativos para aumentar la permeabilidad de la barrera hematoencefalica.
US11160977B2 (en) 2018-09-04 2021-11-02 Novocure Gmbh Delivering tumor treating fields (TTFields) to the infratentorial brain
US11020585B2 (en) 2018-09-07 2021-06-01 Novocure Gmbh Treating autoimmune diseases using an alternating electric field to reduce the proliferation of t-cells
US20200108031A1 (en) 2018-10-05 2020-04-09 Novocure Gmbh Treating Tumors Using TTFields Combined with ABT-751
CN113164525B (zh) 2018-10-23 2025-03-14 利兰·斯坦福青年大学托管委员会 在基于干细胞的疗法中使用交变电场预防和治疗畸胎瘤形成
CN112955208B (zh) 2018-10-25 2024-11-22 诺沃库勒有限责任公司 向受试者的脊柱解剖结构递送交变电场(例如,ttfields)的方法
US20200146586A1 (en) 2018-11-14 2020-05-14 Novocure Gmbh Creating Accurate Computational Head Models of Patients Using Datasets Combining MRI and CT Images
HUE065574T2 (hu) 2018-11-19 2024-06-28 Novocure Gmbh Tömbök daganatkezelõ mezõk (TTFIELD) rendelkezésre bocsátására szelektíven címezhetõ alelemekkel
JP7353363B2 (ja) 2018-11-29 2023-09-29 ノボキュア ゲーエムベーハー TTFields(腫瘍治療電場)を提供するための柔軟性を高めたトランスデューサーアレイ
EP3968279B1 (en) 2019-01-08 2025-01-01 Novocure GmbH Evaluating quality of segmentation of an image into different types of tissue for planning treatment using tumor treating fields (ttfields)

Also Published As

Publication number Publication date
US20240350799A1 (en) 2024-10-24
EP3977991A1 (en) 2022-04-06
JP7714612B2 (ja) 2025-07-29
CN113613651A (zh) 2021-11-05
JP2023171933A (ja) 2023-12-05
US11911610B2 (en) 2024-02-27
EP3988099C0 (en) 2023-06-07
WO2020201967A1 (en) 2020-10-08
EP3988099B1 (en) 2023-06-07
EP3946322A1 (en) 2022-02-09
JP7419391B2 (ja) 2024-01-22
US20200306531A1 (en) 2020-10-01
EP3988099A1 (en) 2022-04-27
EP3946322B1 (en) 2023-09-20
JP2022524824A (ja) 2022-05-10
CN113613651B (zh) 2025-08-12
DK3946322T3 (da) 2023-11-27

Similar Documents

Publication Publication Date Title
DK3946322T3 (da) Fremgangsmåder til genoprettelse af sensitivitet over for ttfields i ttfields-resistente kræftceller med ptger3-inhibitorer
EP3480321B8 (en) Massively parallel single cell analysis
EP2943591A4 (en) METHOD AND COMPOSITIONS FOR PROFILING SINGLE CELL EXPRESSION
IN2015DN00143A (pl)
TWI562171B (en) The composition for forming solar cell electrode and electrode prepared using the same
EP3014664A4 (en) PHOTOVOLTAIC CELL AND LAMINATE METALLIZATION
SI3212225T1 (sl) Postopki in sestavki za modificirane celice T
IL246083A0 (en) A barrier inhibitor and a whole mycobacterium cell, for use in cancer treatment
EP3075009A4 (en) Structures and methods with reduced sensitivity to surface charge
EP3198670A4 (en) Electrochemical cell with protected negative electrode
GB201417240D0 (en) Solar cell with specific front surface electrode design
EP3088526A4 (en) Use of mirna-214 inhibitor in inhibiting regulatory t cells
EP3335245A4 (en) SINTERABLE COMPOSITION FOR USE IN PHOTOVOLTAIC SOLAR CELLS
EP3125341A4 (en) Lead storage cell and electrode collector for lead storage cell
EP3164148A4 (en) Methods and compositions for inhibiting growth and epithelial to mesenchymal transition (emt) in cancer cells
EP3294334A4 (en) Autoimmune antibodies for use in inhibiting cancer cell growth
EP3235011A4 (en) Thick damage buffer for foil-based metallization of solar cells
EP2948762A4 (en) SPECTRAL SEGMENTATION FOR OPTIMIZED SENSITIVITY AND CALCULATION IN ADVANCED RADIATION DETECTORS
SG11201506423RA (en) Ion tolerant corrosion inhibitors and inhibitor combinations for fuels
EP3047275A4 (en) Compositions and methods for increasing mesenchymal stromal cell migration to tumors
FR3007201B1 (fr) Cellule solaire multi-jonctions
EP3259782A4 (en) Damage buffer for solar cell metallization
GB201307320D0 (en) Charge mediators for sensitised solar cells
EP3259576A4 (en) Thin-layer spectroelectrochemistry cell and methods for use in subterranean formation operations
PL3475359T3 (pl) Hydrolitycznie stabilne kompozycje do folii w ogniwach słonecznych